Matricelf Ltd
Matricelf Ltd is a biotechnology company focused on healthcare diagnostics, developing and commercializing innovative diagnostic solutions for medical applications.
Business. Matricelf Ltd (MTLF.TA) is a biotechnology and medical research company focused on healthcare diagnostics. The firm is headquartered in Israel and is primarily listed on the Tel Aviv Stock Exchange. Specific details regarding operating segments and geographic revenue mix are not available.
At a glance
What drives this business
The watch-list the newsroom runs for this company — derived from its sector path, sharpened layer by layer. Not investment advice.
News & coverage
0Sector rotation
Developing storylines
Analysis
AI analysisOpportunity
Upcoming catalysts
Scheduled public events. Informational only — not investment advice.
- Macro
- Rate decisionBank of England rate decision (press conf.)2026-08-06 · GB
- Rate decisionReserve Bank of Australia rate decision (press conf.)2026-08-12 · AU
- Rate decisionNorges Bank rate decision (press conf.)2026-08-20 · NO
- Rate decisionSveriges Riksbank rate decision (press conf.)2026-09-03 · SE
- Rate decisionBank of Canada rate decision (press conf.)2026-09-09 · CA
- Rate decisionEuropean Central Bank rate decision (press conf.)2026-09-10 · EU
- Macro & political
- ElectionSE Swedish Election2026-09-14 · SE
- ElectionUS U.S. Midterms2026-11-03 · US
- ElectionFR French Legislative2027-06-01 · FR
Pre-earnings brief
Signals & dispatch
Composite-score breakdown
Synthesis
Matricelf Ltd (MTLF.TA) is a biotechnology and medical research company focused on healthcare diagnostics. The firm is headquartered in Israel and is primarily listed on the Tel Aviv Stock Exchange. Specific details regarding operating segments and geographic revenue mix are not available.
Matricelf operates with a fully diluted share count of 29.24 million shares, with no difference between basic and diluted shares outstanding, indicating no immediate dilution pressure from stock options or convertible instruments. The company's market price of 278.8 ILS results in a market capitalization of approximately 8.15 billion ILS, but no liquidity metrics are available due to the absence of balance-sheet inputs and lack of going-concern language in source documents.
Profitability and return metrics are not available for Matricelf, as the valuation snapshot does not include key financial ratios such as ROIC, EBITDA margins, or net profit margins. Without these metrics, it is not possible to compare the company's performance to industry benchmarks or cohort medians.
The company's revenue concentration and geographic exposure are not disclosed in the available data. No segment-level revenue breakdown or geographic distribution is provided, making it difficult to assess the diversification of its revenue streams.
Growth trajectory is also unclear, as the outlook section does not provide numeric deltas or forward-looking revenue guidance for the current or next fiscal year. Historical revenue data is not included in the input, limiting the ability to assess growth trends.
Risk factors include the inability to assess liquidity risk due to missing balance-sheet data and no going-concern language in source documents. The company is flagged for potential liquidity risk, but no specific risk severities or composite risk scores are available.
Recent events, including filings or transcripts, are not disclosed in the input data. No specific recent developments or disclosures are available to inform the company's current strategic or operational status.
- Matricelf operates in the healthcare diagnostics segment with a focus on biotechnology.
- The company has no immediate dilution pressure, as basic and diluted shares are equal.
- No liquidity metrics are available, and liquidity risk could not be assessed.
- Profitability and return metrics are not disclosed, limiting performance comparisons.
- Revenue concentration and geographic exposure are not provided in the available data.
- Growth trajectory and recent events are not disclosed, limiting forward-looking visibility.
Bull / Bear case
Generated · model-assistedIn focus — financials by report
Valuation FY
Revenue by segment
Business relationships
Supply chain
Peer comparison
Market position
Stress test
Predictor forecast
Options
Short squeeze
Earnings-call key lines
Estimate revisions
consensus EPS · 26-week trendSell-side observations
Themes
ESG
Risk factors
Benchmarks vs cohort
Corporate actions / M&A
FX exposure
Comparable transactions
Derivatives & instruments
Actions
Ask Handelsavisen
- Market data
- Market data cache
- Issuer disclosures
- Public news
- Earnings transcripts
- Consensus estimates
- ESG data
- Dilution Ratio(shares_outstanding_diluted - shares_outstanding_basic) / shares_outstanding_basic
- Market Priceinput from market-data provider (delayed close or quote-shim mid)
- Market Capmarket_price * shares_outstanding_diluted
- Matricelf Ltd Market data — financials · 2026-05-28